Objective Temporal bone squamous cell carcinoma (TBSCC) is rare and often confers a poor prognosis. The aim of this study was to synthesize survival and recurrence outcomes data reported in the literature for patients who underwent temporal bone resection (TBR) for curative management of TBSCC. We considered TBSCC listed as originating from multiple subsites, including the external ear, parotid, and external auditory canal (EAC), or nonspecifically from the temporal bone. Data Sources PubMed, Cochrane Library, Embase, and manual search of bibliographies. Review Method A systematic literature review conducted in December 2020 according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Results Survival data were collected from 51 retrospective studies, resulting in a pooled cohort of 501 patients with TBSCC. Compared to patients undergoing lateral TBR (LTBR), patients undergoing subtotal (SBTR) or total (TTBR) TBR exhibited significantly higher rates of stage IV disease ( P < .001), positive surgical margins ( P < .001), facial nerve involvement ( P < .001), and recurrent disease ( P < .001). A meta-analysis of 15 studies revealed a statistically significant 97% increase in mortality in patients who underwent STBR or TTBR. On multivariate analysis, recurrent disease was independently associated with worse overall survival ( P < .001). On univariate analysis, facial nerve involvement was also associated with decreased overall survival ( P < .001). Conclusion Recurrent disease was associated with risk of death in patients undergoing TBR. Larger prospective multi-institutional studies are needed to ascertain prognostic factors for a wider array of postoperative outcomes, including histology-specific survival and recurrence outcomes.
Introduction: Hematoma expansion (HE) is a known prognostic indicator of spontaneous intracerebral hemorrhage (sICH). Although several scores exist for prediction of HE, universal adoption has been limited due to their lack of sensitivity and specificity. As machine learning (ML) algorithms have shown promise in the stroke field, here we examine the predictive accuracy of several ML algorithms for HE in sICH patients. Methods: We retrospectively analyzed demographic, clinical data, and radiographic signs of patients with sICH in our 2-hospital database. A total of 61 clinical, imaging, and treatment variables were included in the study. Nine ML models were applied: Adaptive Boost (AdaBoost), Bernoulli Naïve Bayes (BNB), Decision Tree (DT), Gaussian Naïve Bayes (GNB), Logistic Regression (LR), Multi-Layer Perceptron (MLP), Multinomial Naïve Bayes models (MNB), Random Forest (RF), and Extreme Gradient Boosting (XGBoost). All models were trained to predict HE. Model accuracy was assessed using the area under characteristic curve (AUC). Results: Of the 301 patients with sICH, 63 developed HE (21.93%). Of the 9 models studied, MLP had the highest AUC score (0.93±0.042), followed by XGBoost (0.80±0.06). All models demonstrated moderate to high predictive accuracy (AUC 0.64-0.93) for HE. The top predictors in MLP were Baseline NIHSS score, HDL, aPPT, time from last known well to ER, initial hematoma volume, and island sign. MLP had moderate sensitivity of 0.46±0.17 and high specificity of 0.99±0.02. GNB, however, showed the highest sensitivity at 0.86±0.06 and a moderate specificity of 0.65±0.07. Five of the 9 models ranked time last known well to ER presentation as a predictor of HE. Conclusion: In our study, we found all ML models applied had moderate to high predictive accuracy for prediction of HE in sICH, with MLP having the highest accuracy of all models. Future studies examining the use of these algorithms are warranted.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.